Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1/PD-L1 inhibitors for
Yuhan Wei1, Yun Wu1, Yang Luo1
1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Critical Reviews in Oncology/Hematology
|February 29, 2024
Summary
Combining PD-1/PD-L1 inhibitors with chemotherapy improves outcomes for early-stage triple-negative breast cancer (TNBC). This immunotherapy combination enhances pathological complete response and event-free survival in TNBC patients.
Area of Science:
- Oncology
- Immunotherapy
- Breast Cancer Research
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options.
- Chemotherapy is a standard treatment, but outcomes can be improved with novel therapeutic strategies.
- Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have shown promise in various cancers.
Conclusions:
- Adding PD-1/PD-L1 inhibitors to chemotherapy enhances pCR and EFS in early-stage TNBC.
- Tumor stage (T and N) may influence the effectiveness of this combined treatment approach.
- This strategy offers a promising advancement for early TNBC management.
